CNS Pharmaceuticals Inc. CNSP Archives - Page 6 of 22

WednesdayMay 03, 2023 12:26 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Retains Analytics Firm, Investigates Possible Naked Short Selling

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is investigating potential naked short selling of its stock. As part of that process, the company has retained Shareholder Intelligence Services LLC (ShareIntel), a well-known analytics firm. ShareIntel will be evaluating trading patterns of CNSP stock as part of the investigation. “While we are pleased to see the significant price appreciation in our stock as well as an increased high volume of trading activities, our shareholders have expressed concerns that our stock may be…

ThursdayApr 27, 2023 11:25 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate, Present at Upcoming Virtual Investor Spotlight Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor Spotlight Event. The event is titled Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study. According to the announcement, the live, moderated video webcast is scheduled to begin at noon on May 3, 2023, and will feature members of CNS Pharmaceuticals management, including CEO John Climaco; chief medical officer Sandra Silberman, MD, PhD; and VP of clinical operations Zena Muzyczenko. These key executives will discuss the progress…

FridayApr 21, 2023 1:43 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported the enrollment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”). “CNS Pharmaceutical’s adaptive, multicenter, open-label, randomized controlled study targets adult patients with recurrent GBM after failure of standard first-line therapy. In addition, the study will also enroll patients who have received additional treatments as part of the first-line therapy in recognition of the complexity of new agents introduced as a component of this therapy. The study will compare Berubicin, a novel anthracycline and the first anthracycline to…

ThursdayApr 13, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer

Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the lives of more than 200,000 patients worldwide each year CNS Pharmaceuticals is in the middle of a potentially pivotal global Phase 2 clinical trial for its drug candidate, a novel anthracycline called Berubicin that is apparently unique in its ability to cross the blood-brain barrier to target central nervous system tumors CNS’s clinical trial sites have begun enrolling patients in the United States, France, Spain and Switzerland, with sites prepared to receive patients in Italy as…

TuesdayApr 11, 2023 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues

CNS Pharmaceuticals recently announced it had enrolled the first patient in Switzerland as part of its ongoing potentially pivotal global GBM trial The adaptive, multicenter, open-label, randomized controlled trial is evaluating Berubicin for the treatment of recurrent GBM, the most common primary brain cancer, compared to Lomustine, the current standard of care The enrollment moves the company closer to its goal of undertaking an interim analysis expected in the third quarter of 2023 So far, CNS Pharmaceuticals has opened over 40 of 59 planned clinical trial sites selected across Switzerland, Spain, France, Italy, and the U.S. As an aside, the…

MondayApr 10, 2023 1:13 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls Over 100 Patients in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that more than 100 patients have been enrolled in the company’s potentially pivotal study with its lead product candidate, Berubicin. “We have long promised a study with a robust sample size sufficient to effectively determine Berubicin’s therapeutic potential,” said John Climaco, CEO of CNS Pharmaceuticals. “Today’s achievement shows we are doing just that. Enrolling over 100 patients in this relatively rare disease in a little more than 18 months is a remarkable…

ThursdayApr 06, 2023 12:45 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Adds Italy to Growing Portfolio of Countries for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP) today announced its receipt of approval from the Italian Medicines Agency (“AIFA”) Competent Authority and the A.O.U. Policlinico di Bari Ethics Committee for its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. According to the update, the company plans to open its clinical sites in Italy imminently in addition to the previously opened 41 clinical trial sites of the 60 selected across the U.S., France, Spain, and Switzerland. “Our team has continued to make dedicated efforts to build momentum and drive…

MondayApr 03, 2023 12:40 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces FY 2022 Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the full year ended Dec. 31, 2022. The company also provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer. “Over the course of 2022, we made significant advancements in our ongoing clinical trial for Berubicin. We have expanded our clinical trial sites across Europe and continued with an encouraging and increasingly rapid pace of…

WednesdayMar 29, 2023 12:24 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Virtual Investor Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor GBM Spotlight Event. The online event is scheduled for April 4, 2023, at 4:30 p.m. ET. The event will include a live, moderated video webcast with members of CNS Pharmaceuticals management, including CEO John Climaco; the panel will also include key opinion leader, Michael Weller, MD. Weller is an acclaimed neuro-oncologist who currently serves as chair of the Department of Neurology at the University Hospital in Zurich,…

FridayMar 24, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Hits Key Milestone in Global GBM Clinical Trial with the Enrollment of First Patient in Spain

CNS recently enrolled the first patient in Spain in its ongoing global trial evaluating its lead drug candidate, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”) This milestone is the culmination of years of meticulous planning and execution The enrollment of this first patient follows the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma and neuro-oncology, just enrolled its first patient in Spain, marking…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP